We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Immunocore Holdings PLC | NASDAQ:IMCR | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.68 | 2.79% | 61.91 | 60.26 | 63.66 | 62.74 | 59.70 | 60.25 | 473,254 | 01:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Immunocore Holdings PLC on Wednesday said the U.S. Food and Drug Administration has approved Kimmtrak for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.
The Oxfordshire, U.K., biotechnology company said it is ready to commercialize Kimmtrak, and that it expects to make the drug commercially available in the U.S. within weeks.
Immunocore said Kimmtrak is the first TCR therapeutic to receive FDA approval, the first bispecific T-cell engager approved by the FDA to treat a solid tumor, and the first and only therapy approved by the agency for the treatment of unresectable or metastatic uveal melanoma, the most common primary cancer within the eye in adults.
Regulatory agencies in Europe, the U.K., Canada and Australia are currently reviewing Kimmtrak.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 26, 2022 07:35 ET (12:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Immunocore Chart |
1 Month Immunocore Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
